Buz Investors Canopy Growth Added to S&P/TSX - Canopy Growth Corporation (TSX: WEED) ("Canopy Growth" or "the Company") today announced that by being added to the S&P/TSX Composite Index,

Canopy Growth Corporation Reiterates Stance on International Markets

Canopy Growth Corporation Reiterates Stance on International Markets

Buz Investors Canopy Growth Added to S&P/TSX - Canopy Growth Corporation (TSX: WEED) ("Canopy Growth" or "the Company") today announced that by being added to the S&P/TSX Composite Index,

PRESS RELEASE  Canopy Growth Corporation Reiterates In response to multiple media reports regarding US market participation and security regulations, and as stated in a press release dated June 19th, 2017, Canopy Growth Corporation (TSX: WEED) (“Canopy Growth” or the “Company”) wishes to reiterate its commitment to only conducting its business in jurisdictions where it is federally legal to do so.

Canopy Growth believes that conducting activities which are federally illegal, or investing in companies which do, puts the company at risk of prosecution, puts at risk its ability to operate freely, and potentially could jeopardize its listing on major exchanges now and in the future, limiting access to capital from reputable US-based funds.

“Canopy Growth investors can feel confident that they are not being exposed to undue risks,” said Bruce Linton, Chairman & CEO. “We have a responsibility to our shareholders to only operate in a manner where clear federal and fully legal frameworks exist for that conduct.”



Canopy Growth Corporation Reiterates

Exiting prohibition is an exercise in building credibility for a new sector. Numerous international markets exist, as seen by Canopy Growth’s sector-leading expansion efforts in AustraliaGermanyBrazil, and Chile.

Here’s to Future Growth.

About Canopy Growth Corporation
Canopy Growth is a world-leading diversified cannabis company, offering distinct brands and curated cannabis varieties in dried, oil and capsule forms. Through its wholly‑owned subsidiaries, Canopy Growth operates numerous state-of-the-art production facilities with over half a million square feet of GMP-certified indoor and greenhouse production capacity, all to an unparalleled level of quality assurance procedures and testing. Canopy Growth has established partnerships with leading sector names in Canada and abroad, with interests and operations spanning four continents.

Notice Regarding Forward Looking Statements
This news release contains forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Canopy Growth Corporation, Tweed Inc., Tweed Farms Inc., Mettrum Health Corp., or Bedrocan Canada Inc. to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Examples of such statements include future operational and production capacity, the impact of enhanced infrastructure and production capabilities, and forecasted available product selection.  The forward-looking statements included in this news release are made as of the date of this news release and Canopy Growth Corp. does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Neither the TSX Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Exchange) accepts responsibility for the adequacy or accuracy of this release.

 

SOURCE Canopy Growth Corporation

View original content: http://www.newswire.ca/en/releases/archive/August2017/04/c1154.html

Jordan Sinclair, Director of Communications, Jordan@canopygrowth.com, 613-769-4196; Investor Relations: Tyler Burns, Tyler.burns@canopygrowth.com, 855-558-9333 ex 122; Director: Bruce Linton, tmx@canopygrowth.comCopyright CNW Group 2017

Like up on FACEBOOK


logo



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )



Netflix Stock Netflix, Inc. (NASDAQ:NFLX) reported second-quarter earnings this week, and although the NFLX stock price jumped more than 10% in response,

Is Subscriber Growth Enough for Netflix Stock (NFLX)?

Netflix Stock Up After Earnings

FOREX INVESTORS BUZZ

Netflix Stock Netflix, Inc. <span data-recalc-dims=(NASDAQ:NFLX) reported second-quarter earnings this week, and although the NFLX stock price jumped more than 10% in response, " width="300" height="233" srcset="https://i2.wp.com/investorsbuz.com/wp-content/uploads/2017/07/Netflix-Stock-300x233-Small.jpg?resize=300%2C233 300w, https://i2.wp.com/investorsbuz.com/wp-content/uploads/2017/07/Netflix-Stock-300x233-Small.jpg?w=618 618w" sizes="(max-width: 300px) 100vw, 300px" />

 Netflix Stock Netflix, Inc. (NASDAQ:NFLX) reported second-quarter earnings this week, and although the NFLX stock price jumped more than 10% in response, I think we should re-examine why we love Netflix stock. For example, what is the yardstick for measuring NFLX stock?

Revenue? Profit? Cash flow? Of course not. We measure Netflix’s progress by subscriber growth. Which means that the current bump in the NFLX stock price is based on popularity.

In the last quarter, the number of subscribers grew from 99 million to 104 million. Much of the expansion comes from overseas, where Netflix added 5.2 million users in three months. (Source: “Netflix 2017 Second-Quarter Letter to Shareholders,” Netflix, Inc., July 17, 2017.)

That’s all well and good, but investing is a money game.

What Does This Mean for Netflix Stock Price?

This can’t be good for the NFLX stock price. Even if you dig further into Netflix’s past, the trend remains true. In 2014, for instance, the company was spending around $230.00 per customer. (Source: “Netflix 2014 Fourth-Quarter Letter to Shareholders,” Netflix, Inc., January 20, 2015.)

Now let’s put that in context of the Netflix stock price. At the same time that customer acquisition costs were rising, the share price climbed 193%.



 Netflix Stock

NFLX stock chart

 

Investors were (and are, for that matter) so starstruck by Netflix’s subscriber growth that they kept rewarding the company. Never mind that Netflix would need to keep those customers locked in for more than two years before breaking even.

Just to be clear, I don’t think Netflix’s situation is quite as serious as a sinking ship. My main point is that Netflix sends more money out than in and that perhaps we should pay more attention to that fact.

Conclusion

It may surprise you—especially after reading this article—but I am bullish on Netflix stock.

I love Netflix. I use it every day. Heck, Reed Hastings is even one of my favorite CEOs. But that doesn’t mean I follow him blindly. If you don’t want to get sideswiped by “black swans,” you have to consider it from every angle.

Like up on FACEBOOK




Market quotes are powered by
TradingView.com



Tech Stocks ( GOOG)   (MSFT ) ( AAPL ) (BBRY ) ( gopro )  ( WDC )



etra Bio-Pharma Inc. (“Tetra” or the “Company“) (CSE:TBP)(TBP.CN)(CNSX:TBP)(TBPMF), announced today that it will also commercialize novel cannabinoid based formulations for the treatment

Tetra Bio-Pharma Inc. (TBPMF) Accelerates Growth Strategy with Appointment of Bernard Fortier as CEO

Tetra Bio-Pharma Accelerates Growth Strategy with Appointment of Bernard Fortier as CEO

FOREX INVESTORS BUZZ

etra Bio-Pharma Inc the appointment of Bernard Fortier to the position

Tetra Bio-Pharma Inc PRESS RELEASE. (“Tetra” or the “Company“) (CSE:(TBP)(TBP(.CN)(CNSX:(TBP) (TBPMF) today announced that it has strengthened its management team with the appointment of Bernard Fortier to the position of Chief Executive Officer, effective today, July 24, 2017. Mr. Andre Rancourt, previous interim CEO will take the position as Chairman of the Board of Directors. Mr. Andre Audet will step down as Chairman of the Board of Directors but will continue to serve as a Board member.
Bernard Fortier is a graduate from the MBA program at l’école des Hautes Études Commerciales (HEC) in Montreal, with over 20 years of international experience in management and business development in the biopharma, specialized medical nutrition and medical fields.

Mr. Fortier spent 5 years in the USA working in the therapy and rehabilitation market, having graduated from the physiotherapy program at Laval University. His experience in the USA enabled him to work on business development and management early in his career. After completing his MBA in 2001, he joined the pharmaceutical industry with a biotechnology company. He spent 8 years in various key commercial roles at Serono Canada (now EMD Serono) in the Multiple Sclerosis field, including National Sales Manager for the Neurology business unit.

 



Tetra Bio-Pharma Inc.

Cannabis Buzz 

In 2010, Bernard became the Country Manager for Nutricia Canada, the specialized medical nutrition division of Groupe Danone. He was recruited in 2012 to launch a new pharmaceutical company called Orimed Pharma. Through licensing deals and internal product development, the company’s portfolio grew from 3 to 10 products within 4 years.

“I am very pleased to welcome Bernard to the team as our new CEO as we are focused on building Tetra as a leading bio-pharmaceutical organization,” said Andre Rancourt, Chairman of Tetra Bio-Pharma. “Bernard is an experienced leader and executive with proven skills in leadership, strategy and execution, as well as business development and negotiation. Mr. Fortier has a clear mandate from the Board, to grow revenue and build Tetra as a global leader in pharmaceutical cannabis. Going forward, we will be placing considerable efforts in expanding Tetra in the U.S. market.”

Corporate Update:

Mr. Andre Rancourt, previous interim CEO was elected to the position as Chairman of the Board of Directors. The Board has mandated Mr. Rancourt to continue taking an active and dynamic role as he demonstrated as Interim CEO. Mr. Rancourt will be responsible for the administration, overall corporate governance and financing of the corporation.

Mr. Andre Audet will step down as Chairman of the Board of Directors but will continue to serve as a member of the Board. The Corporation wishes to thank Mr. Audet for all his efforts in working to grow Tetra where it is today and looks forward to his continued participation in building Tetra as a global leader in pharmaceutical cannabis.

About Tetra Bio-Pharma:

Tetra Bio-Pharma is a multi subsidiary publicly traded company (CSE:TBP)(TBP.CN)(CNSX:TBP)(TBPMF) engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.

Tetra Bio-Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators physicians and insurance companies. More information is available about the company at: www.tetrabiopharma.com.

The Canadian Securities Exchange (“CSE”) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Like up on FACEBOOK


logo



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )



 Philly Fed Index  Philadelphia-area manufacturing activity grew at a notably slower rate in the month

Philly Fed Index Indicates Notably Slower Growth In July

Philly Fed Index Indicates Notably Slower Growth In July

PhiladelphiaFed-072017-lt.jpg

FOREX INVESTORS  Philly Fed Index  Philadelphia-area manufacturing activity grew at a notably slower rate in the month of July, according to a report released by the Federal Reserve Bank of Philadelphia on Thursday.

The Philly Fed said its index for current manufacturing activity in the region slumped to 19.5 in July from 27.6 in June.

While a positive reading still indicates growth in regional manufacturing activity, economists had expected the index to show a much more modest drop to 24.0.

The bigger than expected decrease by the headline index was partly due to a notable slowdown in the pace of growth in new orders, as the new orders index tumbled to 2.1 in July from 25.9 in June.



 Philly Fed Index  

The shipments index also slid to 12.2 in July from 28.5 in June, while the number of employees index fell to 10.9 from 16.1.

The report said the prices paid index also dipped to 19.1 in July from 23.6 in June, and the prices received index dropped to 9.0 from 20.6.

Looking ahead, the Philly Fed said the survey’s six-month indicators remained positive in July, with firms generally expecting growth to continue.

The diffusion index for future general activity climbed to 36.9 in July from 31.3 in June, as over half of the manufacturers expect increases in activity over the next six months.

On Monday, the New York Fed released a separate report showing activity in the New York manufacturing sector also grew at a notably slower pace in July.

The New York Fed said its general business conditions index dropped to 9.8 in July from 19.8 in June. Economists had expected the index to fall to 15.0.

Like up on FACEBOOK


logo

Market quotes are powered by
TradingView.com



Tech Stocks ( GOOG)   (MSFT ) ( AAPL ) (BBRY ) ( gopro )  ( WDC )



 Isodiol International Inc

Isodiol International Inc. signs Definitive Licensing Agreement with Canopy Growth Corporation for Canadian and International Distribution

Isodiol International Inc. signs Definitive Licensing Agreement with Canopy Growth Corporation for Canadian and International Distribution

 

 

 Isodiol International Inc

FOREX INVESTORS  PRESS RELEASE  Isodiol International Inc. (CSE: ISOL) (OTC: LAGBF) (Frankfurt: LB6A.F) (the “Company” or “Isodiol”) a global cannabis innovator specializing in the development of pharmaceutical and consumer products is pleased to announce it has signed a licensing agreement with Canopy Growth Corporation (“Canopy”) (TSX:WEED) (https://www.canopygrowth.com).

Canopy Growth is the world’s premier cannabis company that operates a collection of diverse brands and curated strain varieties, supported by over half a million square feet of indoor and greenhouse production capacity. Under this licensing agreement, Canopy Growth will have the right to manufacture and distribute the Company’s “Pot-O-Coffee” and “Pot-O-Tea” branded marijuana infused single serve K-Cup products in Canada and certain other markets internationally as federal regulations allow.  Licensed products include caffeinated and de-caffeinated product lines as well as Isodiol’s single serve “Pot-O-Coco”.  In addition to the Canadian rights, Canopy Growth shall have the right of first refusal to sell the “Pot-O” brand products in any territory outside of the US, Mexico and Puerto Rico.

“This distribution agreement has us positioned to increase our global footprint with the largest cannabis company in the world.  We will continue to develop our Pot-O-Coffee product lines with ready to drink and cold brew products while working with Canopy Growth for international distribution channels.  The Pot-O-Coffee brand is well recognized, and adding additional products to this line will continue to strengthen its market presence,” stated Isodiol’s CEO Marcos Agramont.



 Isodiol International Inc

The availability of the various licensed products in Canada and elsewhere will differ depending on applicable laws and regulation.  While Canadian law does not yet permit the manufacture and sale of marijuana infused products, the Company anticipates that such products will be permitted in the near future.  Furthermore, currently proposed regulations which would permit the sale of infused products, would not allow such products to contain both marijuana and caffeine.  As such, the specific product offerings in Canada and elsewhere may be limited. The Company will provide additional updates as regulations are adopted and as product roll-out plans are developed.

About Isodiol International Inc.

Isodiol International, Inc. is the market leader in pharmaceutical grade cannabis compounds and the industry leader in manufacturing and development of consumer products. Isodiol’s nutraceutical division is the pioneer of many firsts for Hemp-derived cannabidiol (CBD), including 99% pure crystalline isolate, micro-encapsulation, and nano technology for the highest quality consumable and topical skin care products.

Isodiol’s growth strategy includes the development of over-the-counter and pharmaceutical drugs, seeking joint ventures and acquisitions to expand its portfolio of brands and subsidiaries and will aggressively continue International expansion into Latin America, Asia and Europe.

Like up on FACEBOOK


logo



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )



Bitconnect Coin Price Last month on the 10th of June, the Bitconnect coin, better known to the community as BCC, reached an all-time

Bitconnect Coin Price Reaches All-Time High in June, Briefly Surpasses Growth Rate of Ethereum

Bitconnect Coin Price Reaches All-Time High in June, Briefly Surpasses Growth Rate of Ethereum

Bitconnect Coin Price Last month on the 10th of June, the Bitconnect coin, better known to the community as BCC, reached an all-time

FOREX INVESTORS BUZZ PRESS RELEASE Bitconnect Coin Price Last month on the 10th of June, the Bitconnect coin, better known to the community as BCC, reached an all-time high price at $59.24. The price of BCC increased from $1.76 to $59.24 within a three-month period, recording a staggering growth rate of 3,265 percent.

Since the beginning of 2017, the cryptocurrency market demonstrated an exponential growth rate, achieving a historic milestone on June 9 by surpassing $100 billion in market cap. Prior to this recent dip, the cryptocurrency market cap was valued to be $113 million at one point, with Bitcoin capturing 37.8 percent of the market.

“The fact that these gains have come from currencies other than Bitcoin are a good sign that this is less of a bubble and more of a resurgence of interest in crypto,” said Techcrunch journalist Fitz Tepper.

A major catalyst that contributed to the rapid growth of the cryptocurrency market was the global adoption of Bitcoin and Ethereum, two of the largest cryptocurrencies with a combined market cap of $77.6 billion. Since mid-2016, the demand toward Bitcoin as a safe haven asset and digital gold surged as mainstream media outlets began to provide extensive coverage on its performance.

 



Bitconnect Coin Price

International newspapers including the Wall Street Journal continuously featured Bitcoin on their front page, comparing the price trend of it to that of gold and the US dollar, the world’s largest asset and reserve currency.

As interest and demand toward digital currencies such as Bitcoin and Ethereum increased, a growing number of investors started to take interest in other cryptocurrencies in the market such as Litecoin, Ethereum Classic and Bitconnect that are amongst the largest cryptocurrencies and networks.

At the time of reporting, the market cap of Bitconnect, a crypto-network better known for its bitcoin lending platform, remains at around $346 million, making the Bitconnect network the 22nd largest cryptocurrency and blockchain network globally (editor’s note: the Bitconnect network is now ranked 10th).

Bitconnect’s three-month growth since April has been larger than that of most cryptocurrencies including Ethereum. Since April, Ethereum has recorded a 858.9 percent increase in price, from $39 to a peak at $374, triggering the interests of investors that have become enthusiastic of the launch of the Enterprise Ethereum Alliance (EEA) and the rise of initial coin offerings (ICOs).

|Chart | Calendar   | TRADE NOW | FORCAST | cryptocurrency 

Market Quotes by TradingView

Like up on FACEBOOK


logo



BUZ INVESTORS CANNABIS INVESTMENT OPPORTUNITY— HelloMD, one of the nation’s largest community of medical cannabis patients, experts and trusted brands, announced today that it has partnered with SeedInvest,

United States Legal Marijuana Market Report 2017: Market Size, Growth Rate, Revenue Forecasts 2016-2021

United States Legal Marijuana Market Report 2017: Market Size, Growth Rate, Revenue Forecasts 2016-2021

BUZ INVESTORS CANNABIS INVESTMENT OPPORTUNITY— HelloMD, one of the nation’s largest community of medical cannabis patients, experts and trusted brands, announced today that it has partnered with SeedInvest,

FOREX INVESTORS   PRESS Release Legal Marijuana Market  Research and Markets has announced the addition of the “The United States Legal Marijuana Market 2017” report to their offering.

A comprehensive look at the legal marijuana industry in the United States. This market analysis includesmarket sizing, market share by competitors, drivers, restraints, challenges, market trends, political insights, technology trends and market forecasts to 2021.

The report features an analysis of companies that operate in the legal marijuana industry. It also provides an understanding of wholesale legal marijuana market segments in the U.S.

The segments not only include companies that grow and directly handle marijuana (legal and recreational) but also include ancillary companies that provide services to the legal marijuana market in some form including hemp, growing equipment, consulting services, laboratory testing, security services and insurance.

 



Legal Marijuana Market

This study captures the following information on the Legal Marijuana Market in the United States:

  • Market Size, Growth Rate, Revenue Forecasts (2016-2021)
  • Growth Drivers & Restraints
  • Market Data
  • Market Share Analysis
  • Market Trends

Market Segmentation:

  • Cultivation: This segment includes the companies that grow cannabis. These companies may or may not have retail operations.
  • Hemp and Marijuana Products: This segment includes companies that manufacture cannabinoid (CBD), and related products – hemp-infused beverages, edibles, topicals, strains, among others.
  • Vaporizers: This segment includes companies that design, manufacture, sell and distribute vaping devices (vaporizers) and cartridges.
  • Ancillary Products: This segment includes cannabis packaging companies, security services, insurance services, and companies that develop analyzers.
  • Consulting & Services: This segment includes companies offering consulting and advisory services, including cannabis testing labs.
  • AG Tech (Agricultural Technology): This segment includes companies that utilize technology to improve cannabis cultivation yields and efficiencies.

Key Topics Covered:

I. Scope of Research

II. Terms & Definitions

III. Research Methodology

IV. Executive Summary

V. United States Legal Marijuana Market

VI. Market Data.

VII. Strategic Recommendations.

VIII. Game Changers.

Companies Mentioned

  • Acology
  • AeroGrow International Inc.
  • American Cannabis Company
  • American Green
  • Americann Inc.
  • Blue Line Protection Group
  • Cana Security America
  • CannLabs Inc.
  • CV Sciences Inc.
  • DigiPath Inc.
  • General Cannibas Corporation
  • Golden Leaf Holdings
  • Great Spirit Inc.
  • Greengro Techs Inc.
  • GrowGeneration Corporation
  • Growlife
  • Helix TCS Inc.
  • Hemp Inc.
  • HempLife Today
  • Kaya Holdings Inc.
  • Kush Bottles Inc.
  • mclg
  • Medical Marijuana
  • Medicine Man Technologies Inc.
  • MyDX Inc.
  • Rocky Mountain High
  • Signal Bay
  • Sugarmade
  • Surna Inc.
  • Terra Tech Corporation
  • Vape Holdings Inc.
  • Vapir Enterprises
  • Vapor Corporation

For more information about this report visit https://www.researchandmarkets.com/research/dkd3t3/the_united_states

Like up on FACEBOOK


logo



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )



German factory orders rose more than expected in August

US Factory Growth At 9-Month Low: PMI

US Factory Growth At 9-Month Low: PMI

BUZ INVESTORS   US Factory Growth  The IHS Markit US Manufacturing PMI fell to 52.1 in June of 2017 from 52.7 in May and well below market expectations of 53, flash estimates showed. It is the lowest reading since September of 2016 as output and new business growth slowed, offsetting stronger contributions from job creation and inventory building.

Meanwhile, latest survey data revealed a marked slowdown in input price inflation to its weakest since March 2016. Lower cost pressures led to a moderation in factory gate price inflation in June. The latest rise in manufacturers’ output charges was the least marked since September 2016.




US Factory Growth

 

Commenting on the flash PMI data, Chris Williamson, Chief Business Economist at IHS Markit said:
“The economy ended the second quarter on a softer note. The June PMI surveys showed some pay-back after a strong May, indicating the second weakest expansion of business activity since last September.

“The average expansion seen in the second quarter is down on that seen in the first three months of the year, indicating a slowing in the underlying pace of economic growth. While official GDP data are expected to turn higher in the second quarter after an especially weak start to the year (our recent GDP tracker based on various official and survey data points to 3.0% growth), the relatively subdued PMI readings suggest there are some downside risks to the extent to which GDP will rebound.

“Historical comparisons of the PMI against GDP indicates that the PMI is running at a level broadly consistent with the economy growing at a 0.4% quarterly rate (1.5% annualized) in the second quarter, or just over 2% once allowance is made for residual seasonality in the official GDP data.

“There are signs, however, that growth could pick up again: new orders showed the largest monthly rise since January, business optimism about the year ahead perked up and hiring remained encouragingly resilient. The survey is indicative of non-farm payroll growth of approximately 170,000.

“Average prices charged for goods and services meanwhile showed one of the largest rises in the past two years, pointing to improved pricing power amid healthy demand.”Like up on FACEBOOK


logo



major currencies: (EUR-USD) (USD-JPY) (USD-GBP) (USD-CHF), (USD-CAD), (AUD-USD) (USDCNY)




In a message seemingly tailored to the Trump Administration’s focus on U.S. paramountcy, Mr. Girling also said the $8-billion (U.S.) pipeline project will strengthen U.S. energy security, support tens of thousands of direct and indirect jobs, and contribute approximately $3.4-billion to U.S. GDP. He noted that TransCanada employees live in 38 U.S. states where the Calgary-based firm operates, and the company is committed to working productively with stakeholders and tribal leaders. “The project is an important new piece of modern U.S. infrastructure that secures access to an abundant energy resource produced by a neighbour that shares a commitment to a clean and healthy environment,” Mr. Girling said. On Wednesday, Mr. Girling told an audience at the CIBC Whistler Institutional Investor Conference that the company has only just re-engaged with potential shippers to see if they’re still interested in committing to the project. Keystone XL was first envisioned in 2008, a time when crude oil prices topped $100 (U.S.) a barrel, and before Canadian oil producers faced intense competition from U.S. shale.

UK Q1 GDP Growth Confirmed At 2% YoY

UK Q1 GDP Growth Confirmed At 2% YoY

BUZ INVESTORS  UK Q1 GDP Growth UK’s gross domestic product expanded 2 percent year-on-year in the first quarter of 2017, following a 1.9 percent growth in the previous period and in line with the previous estimate. Fixed investment rose at a faster pace, with business investment increasing for the first time in over a year, while household spending growth slowed and net trade contributed negatively.

On the expenditure side, gross fixed capital formation went up at a faster 2 percent (1 percent in Q4), as business investment rebounded by 0.7 percent, following four consecutive quarters of decline. Also, household expenditure grew by 2.6 percent (2.9 percent in Q4) and government spending by 0.8 percent (0.4 percent in Q4).

Imports jumped 3.3 percent, following a 2 percent gain in Q4; while exports rose at a slower 2.9 percent, after rising by 0.6 percent the previous period. As a result, the trade deficit widened to £13.7 billion from £12.8 billion in Q1 2016.




UK Q1 GDP Growth 

 

On the production side, the service industries expanded 2.3 percent (2.9 percent in Q4), as output rose for: Distribution, hotels and restaurants (3.5 percent from 6 percent in Q4); transport storage and communications (3.2 percent from 4.4 percent); business services and finance (2.4 percent from 2.3 percent); and government and other services (1.1 percent from 1.2 percent). Industrial production rose at a faster 2.3 percent (1.9 percent in Q4), as manufacturing growth accelerated (2.5 percent from 2 percent in Q4), and mining and quarrying rebounded (1.1 percent from -3 percent). Meanwhile, output rose at a slower pace for electricity, gas, steam and air conditioning supply (0.7 percent from 5.4 percent in Q4); and water supply, sewerage, waste management and remediation activities (3.8 percent from 5.3 percent). Construction expansion was unchanged at 2.8 percent.

Like up on FACEBOOK


logo



major currencies: (EUR-USD) (USD-JPY) (USD-GBP) (USD-CHF), (USD-CAD), (AUD-USD) (USDCNY)